Evidence map›Paper›PMID 40274746›Full record

ArticleJournal of general internal medicine2026

Annual Out-of-Pocket Medical Costs and Financial Toxicity Among Transplant Recipients in the United States.

Gabrielle Jutras, Tracy K Lin, Jennifer C Lai, Sharad I Wadhwani

Abstract read
In one paragraph

Article in Journal of general internal medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Gabrielle JutrasDivision of Hepatology, Department of Medicine, Centre Hospitalier de l'Université de Montréal, Montreal, Quebec, Canada.ORCID 0000-0003-2319-3880
Tracy K LinDepartment of Social and Behavioral Sciences, University of California - San Francisco, San Francisco, CA, USA.
Jennifer C LaiDivision of Gastroenterology and Hepatology, Department of Medicine, University of California - San Francisco, San Francisco, CA, USA.
Sharad I WadhwaniDepartment of Pediatrics, University of California - San Francisco, San Francisco, CA, USA. Sharad.wadhwani@ucsf.edu.

Funding

UCSF Liver Core CenterP30DK026743 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Jennifer C. Lai · 1986 to 2026
$30.7M
Addressing social adversity to improve outcomes among children undergoing liver transplant: the role for a health advocate on the transplant teamK23DK132454 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI WADHWANI, SHARAD · 2022 to 2025
$860k
The Impact of Frailty on Liver Transplant Outcomes in Older Adults with Hepatocellular CarcinomaK24AG080021 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Jennifer C. Lai · 2023 to 2026
$755k
Division of Diabetes, Endocrinology, and Metabolic Diseases K23DK132454NIA NIH HHS K24AG080021NIDDK NIH HHS K23 DK132454NIDDK NIH HHS P30 DK026743
6 · The paper itself

Abstract

backgroundThe significant financial costs associated with solid-organ and bone marrow transplantation incurred by the United States' (U.S.) health systems are well documented. However, the out-of-pocket (OOP) costs and the risk of financial toxicity - defined as economic stress from OOP expenses relative to available resources - for transplant recipients remain poorly characterized.

methodsWe assessed annual OOP medical expenses for transplant recipients using the Medical Expenditure Panel Survey (MEPS) from 2016 to 2020 (n = 201 patients representing N = 466,016) and calculated yearly medical care expenses and insurance premiums. Logistic regressions were performed to analyze risk factors for financial toxicity, using income category and insurance status as indicators of socioeconomic status.

resultsThe mean annual OOP expense was $4034 (SE 508), with insurance premiums and medications being the most significant costs. Among transplant recipients, 12% (SE 3) experienced high financial toxicity. Low-income patients, compared to high-income patients, were nine times more likely to experience financial toxicity (OR 9.3, p = 0.001), with privately insured low-income patients at the highest risk (OR 7.4, p <0.001). Financial toxicity was associated with delayed medication refills due to costs (12% vs 3%, p < 0.05), poorer perceived health status (27% vs 9%, p = 0.05), and increased anxiety (47% vs 20%, p < 0.05).

conclusionsLow-income transplant recipients with private insurance are particularly vulnerable to financial toxicity. Future research should examine the health effects of financial toxicity to enable development of health system and policy interventions aimed at mitigating financial toxicity in this population.

Indexed as

Financial StressHealth ExpendituresTransplant RecipientsAdolescentAdultAgedFemaleHumansMaleMiddle AgedUnited StatesYoung Adultfinancial toxicityhealth statusincomeinsuranceorgan transplantation

Identifiers

PMID40274746
PMCPMC12894561

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.